NSU-MD Faculty Articles
Combination therapy for renal cell cancer: what are possible options?
Publication Title
Oncology
Publisher
S. Karger AG
ISSN
0030-2414
Publication Date
1-1-2011
Keywords
Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Neovascularization, Pathologic
Abstract
Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in patients with RCC and are approved by the US Food and Drug Administration for treatment of this cancer. In practice, the clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived. To improve efficacy, combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities. Recent advances in the molecular understanding of tumor angiogenesis and mechanism of resistance, along with the rapid development of targeted drug discovery, have made it possible to further explore novel combination therapy for RCC.
DOI
10.1159/000333470
Volume
81
Issue
3-4
First Page
220
Last Page
229
Disciplines
Medicine and Health Sciences
NSUWorks Citation
Santos, Napoleon; Wenger, Justin B; Havre, Pamela; Liu, Yanxia; Dagan, Roi; Imanirad, Iman; Ivey, Alison M; Zlotecki, Robert A; Algood, Chester B; Gilbert, Scott M; Allegra, Carmen J; Okunieff, Paul; Vieweg, Johannes; Dang, Nam H; Luesch, Hendrik; and Dang, Long H, "Combination therapy for renal cell cancer: what are possible options?" (2011). NSU-MD Faculty Articles. 61.
https://nsuworks.nova.edu/hpd_md_facarticles/61
